Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic CholangiocarcinomaXinhua Song, Xianqiong Liu, Haichuan Wang, et al.
Journal of Translational Medicine|October 15, 2016
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based studyGrazia Palomba, Valentina Doneddu, Antonio Cossu, et al.
Journal of Translational Medicine|August 31, 2012
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from SardiniaGrazia Palomba, Maria Colombino, Antonio Contu, et al.
Cancers|February 24, 2024
Identification of Tissue miRNA Signatures for Pancreatic Ductal AdenocarcinomaCarlo Caputo, Michela Falco, Anna Grimaldi, et al.
Hepatology (Baltimore, Md.)|April 4, 2017
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesisPin Liu, Mengmeng Ge, Junjie Hu, et al.
Cancers|August 28, 2025
Clinical, Histopathological, Dermoscopic Features, and BRAF, NRAS, and Cell Cycle Genes' Mutation Status in Cutaneous MelanomaMaria A Pizzichetta, Jerry Polesel, Maria C Sini, et al.
Journal of Hepatology|July 23, 2017
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in miceShanshan Zhang, Xinhua Song, Dan Cao, et al.
BMC Cancer|May 10, 2015
Genome-wide association study of susceptibility loci for breast cancer in Sardinian populationGrazia Palomba, Angela Loi, Eleonora Porcu, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Pageof 16